February 7, 2019 10:44 AM EST

Equillium's immuno-inflammatory drug wins FDA's orphan drug status; Vanda sues FDA for mandating lengthy dog study

ENDPOINTS

→ San Diego-based Equillium has nabbed an orphan drug designation for EQ001 on the verge of beginning a Phase Ib/II for the immuno-inflammatory drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Equillium's immuno-inflammatory drug wins FDA's orphan drug status; Vanda sues FDA for mandating lengthy dog study

ENDPOINTS

Sign up to read this article for free.

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Equi­l­li­um's im­muno-in­flam­ma­to­ry drug wins FDA's or­phan drug sta­tus; Van­da sues FDA for man­dat­ing lengthy dog study

ENDPOINTS

Sign up to read this article for free.

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Equillium's immuno-inflammatory drug wins FDA's orphan drug status; Vanda sues FDA for mandating lengthy dog study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?